Recently, cereblon was identified to be the target structure of lenalidomide and pomalidomide [31, 42, 43], and the subsequent enhanced degradation of cereblon-binding proteins like Ikaros, Aiolos and KPNA2 [31, 44] is responsible for the anti-tumor and immunostimulating effect of lenalidomide and pomalidomide [45, 46]. Here, KPNA2 is linked to neoplasm.